Medicare advisory panel to hold meeting:
This article was originally published in Clinica
Executive Summary
The Medicare coverage advisory committee's panel on laboratory and diagnostic services will convene next month to discuss whether the US federal health plan for the elderly and disabled should cover human tumour assay systems that detect resistance or sensitivity to chemotherapeutic agents. The Health Care Financing Administration (HCFA), which administers Medicare, currently considers such tests experimental and therefore declines to cover them. Three groups - including companies Oncotech of Irving, California and Rational Therapeutics of Long Beach, California - have asked HCFA to alter its coverage policy. The two-day event will take place on November 15 and 16 in Baltimore and will be the first public meeting of the laboratory panel.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.